Sangamo Therapeutics
Open
$0.12
Prev. Close
$0.12
High
$0.12
Low
$0.12
Market Snapshot
$44.69M
-0.4
-0.52
$57.8M
183
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Richmond California, California and currently employs 183 full-time employees. The company went IPO on 2000-04-06. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
emptyResult
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Richmond California, California and currently employs 183 full-time employees. The company went IPO on 2000-04-06. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
Recently from Cashu
Sangamo Therapeutics: Key Developments and Future Prospects in Gene Therapy
Please provide the content you would like me to summarize, and I'll be happy to help.
It seems there was a misunderstanding, as no specific content was provided for summarization. Please share the content you'd like summarized, and I'll be glad to assist you!
Please provide the content you would like me to summarize, and I'll be happy to help!
Recent Developments in Sangamo Therapeutics Stock Performance and Market Outlook
It appears that there is no content provided to summarize. Please provide the text or details about Sangamo Therapeutics or any recent developments related to the company, and I'll be happy to assist…
Sangamo Therapeutics: Leading Innovations in Gene Therapy and Strategic Collaborations for Growth
### Sangamo Therapeutics: Advancements in Gene Therapy and Regulatory Milestones Sangamo Therapeutics is at the forefront of pioneering advancements in gene therapy, particularly through its innovativ…